Treatment of cardiovascular disease with quinolinone enantiomers

Abstract

The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

1 . A method, comprising: 
 a) providing: 
 i) a subject suffering from a symptoms of cardiovascular disease and;  
 ii) a purified enantiomer preparation of flosequinan and;  
   b) administering said preparation to said subject under conditions such that said symptom is reduced.    
     
     
         2 . The method of  claim 1 , wherein said purified enantiomer of flosequinan is the (+) enantiomer.  
     
     
         3 . The method of  claim 1 , wherein said purified enantiomer of flosequinan is the (−) enantiomer.  
     
     
         4 . The method of  claim 1 , wherein said enantiomer of flosequinan is introduced into said subject by oral administration.  
     
     
         5 . The method of  claim 4 , wherein said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.  
     
     
         6 . The method of  claim 1 , wherein said enantiomer of flosequinan is introduced into said subject cutaneously.  
     
     
         7 . The method of  claim 1 , wherein said subject has not been treated in the past with a drug that causes hypotensive effects.  
     
     
         8 . The method of  claim 1 , wherein said subject is not being treated with a nitrite or nitrate.  
     
     
         9 . The method of  claim 8 , wherein said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.  
     
     
         10 . A method, comprising: 
 a) providing: 
 i) a subject suffering from a symptom of a cardiovascular disease selected from the group of hypertension and congestive heart failure and;  
 ii) a purified enantiomer preparation of flosequinan and;  
   b) administering said preparation to said subject under conditions such that said symptom is reduced.    
     
     
         11 . The method of  claim 10 , wherein said purified enantiomer of flosequinan is the (+) enantiomer.  
     
     
         12 . The method of  claim 10 , wherein said purified enantiomer of flosequinan is the (−) enantiomer.  
     
     
         13 . The method of  claim 10 , wherein said enantiomer of flosequinan is introduced into said subject by oral administration.  
     
     
         14 . The method of  claim 13 , wherein said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.  
     
     
         15 . The method of  claim 10 , wherein said enantiomer of flosequinan is introduced into said subject cutaneously.  
     
     
         16 . The method of  claim 10 , wherein said subject has not been treated in the past with a drug that causes hypotensive effects.  
     
     
         17 . The method of  claim 10 , wherein said subject is not being treated with a nitrite or nitrate.  
     
     
         18 . The method of  claim 17 , wherein said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.  
     
     
         19 . A purified flosequinan enantiomer preparation comprising a carrier.